trending Market Intelligence /marketintelligence/en/news-insights/trending/AhLtrXmqQ4gUBhLf20qKXw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lixte terminates license agreement with Taipei Medical University

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Lixte terminates license agreement with Taipei Medical University

Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.

The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.